Phil Palumbo, head of equity strategy at Brixton Capital, reaffirmed confidence in Salesforce’s core business, stating that there is "nothing broken" in the company’s operations. He highlighted the company’s leadership in customer-relationship management and its ability to weather sector volatility, noting that key product lines continue to see double-digit annual contract value (ACV) growth. Palumbo cited Salesforce’s disciplined expense management and expanding profit margins as evidence that the stock remains undervalued relative to peers, even after a sustained market downturn for technology names.

Salesforce has deepened its presence in the life-sciences sector through a new integration with Viz.ai. The collaboration will embed Viz.ai’s real-time clinical intelligence—sourced from nearly 2,000 U.S. hospitals covering some 230 million patient lives—into Agentforce Life Sciences workflows. Over 110 pharmaceutical and biotech firms have already adopted Agentforce Life Sciences in the past year. This partnership enables closed-loop, guideline-based engagements across sales, medical-science liaisons and patient-support teams, promising to reduce patient onboarding drop-off by automating enrollment, benefits verification and prior-authorization processes at the point of care.

Salesforce now trades at a free-cash-flow multiple of approximately 14 times, reflecting a strategic shift toward profitability without sacrificing growth. The company’s AI-driven Agentforce product saw its annual recurring revenue jump 330% year-over-year to $540 million, substantially accelerating platform revenue growth. Remaining performance obligations rose by 12% year-over-year, underpinning management’s target of a 10% compound annual revenue growth rate through fiscal 2030 and an ambitious $60 billion revenue goal. Investors are watching closely as the company balances disciplined cost controls with sustained investment in AI and platform extensions.